Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

CureVac Drops on Report of Delayed EMA Approval

Published 2021-06-08, 10:39 a/m
Updated 2021-06-08, 10:39 a/m
© Reuters.

By Christiana Sciaudone

Investing.com -- CureVac NV (NASDAQ:CVAC) tumbled almost 13% after Reuters reported the European Medicines Agency is unlikely to make a decision on its vaccine before August.

German health minister Jens Spahn provided the update on the EMA's view on the timing of the review on Monday in a call with his regional state counterparts, Reuters said, citing a source at the health ministry familiar with the matter. 

In November, CureVac secured a deal to provide up to 405 million doses of the vaccine to the EU, followed by a memorandum of understanding with Germany for another 20 million doses. Those deals hinge on approval from the EMA. 

CureVac already delayed guidance on its initial testing results.

    

 

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.